Globus Medical Inc. (NYSE:GMED) ranks among the best mid-cap stocks with huge upside potential. Following the publication of Globus Medical Inc. (NYSE:GMED)’s second-quarter 2025 results, Citizens JMP reaffirmed its Market Perform rating on the company on August 20.
Likoper/Shutterstock.com
Globus Medical Inc. reported a total sales increase of 3% year-over-year, or 5% on a day-adjusted basis, slightly above analyst expectations. The company’s adjusted earnings per share came in at $0.86, exceeding Street projections of $0.75 by around 15%.
The medical device manufacturer reported that product supply “dramatically improved” throughout its business, and that operational issues that were mentioned in the first quarter had mostly dissipated. The results revealed a turnaround in Enabling Technologies revenue, which was down 4% year-over-year but surged nearly 60% sequentially after a 31% year-over-year drop in the first quarter of 2025.
Medical device manufacturer Globus Medical Inc. creates and markets healthcare solutions for musculoskeletal conditions both nationally and internationally.
READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.
This article is originally published at Insider Monkey.
